Bone marrow-derived stem cells and granulocyte colony-stimulating factor have been proved to contribute to tissue regeneration after liver injury.
Dr Lorenzini and colleagues from Italy tested the safety of granulocyte colony-stimulating factor.
The researchers defined the exact dose capable of mobilizing bone marrow-derived stem cells in the majority of patients with liver cirrhosis.
The research team assessed the feasibility of leukapheresis to collect bone marrow-derived stem cells from peripheral blood.
|No severe adverse events were observed during stem cell collection|
|Alimentary Pharmacology & Therapeutics|
The team treated 18 patients affected by liver cirrhosis.
The patients were treated with increasing doses of granulocyte colony-stimulating factor to mobilize CD34+ and CD133+ bone marrow-derived stem cells into the peripheral blood.
The dose-finding phase demonstrated that 15 µg/kg/day of granulocyte colony-stimulating factor is the optimal dose to mobilize both CD34+ and CD133+ stem cells.
The team collected circulating bone marrow-derived stem cells by a single step leukapheresis in 3 patients.
The mean number of CD34+ and CD133+ cells cryopreserved was 1.3 and 1.2 × 106/kg, respectively.
No severe adverse events were observed during the drug administration and stem cell collection.
The research team noted that none of the patients showed a significant modification of liver function.
Dr Lorenzini's team concluded, "Our study demonstrates that granulocyte colony-stimulating factor administration, and bone marrow-derived stem cells collection from the peripheral blood is possible and safe in patients with liver cirrhosis."
"The optimal dose to mobilize bone marrow-derived stem cells in cirrhotics is 15 µg/kg/day.
"At this dose, granulocyte colony-stimulating factor does not seem to modify the residual liver function in cirrhotic patients."